MAX2—a convenient index to estimate the average per patient risk for chemotherapy toxicity
- 1 May 2004
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (8) , 1193-1198
- https://doi.org/10.1016/j.ejca.2004.01.028
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot studyEuropean Journal Of Cancer, 2002
- Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancerLung Cancer, 2001
- Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2001
- Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter TrialJournal of Clinical Oncology, 2001
- Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2000
- Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II StudyJournal of Clinical Oncology, 2000
- Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group TrialJournal of Clinical Oncology, 2000
- Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2000
- Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.Journal of Clinical Oncology, 1997